Copyright (c) 2024 European Atherosclerosis Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- Articles
-
Published: August 31, 2024
Abstract
The relationship between plasma cholesterol levels and the risk of cardiovascular events is well known. When analysing plasma cholesterol levels and integrating data from several studies, including the Pooling Project, the Framingham Heart Study and the Israeli Perspective Study, a consistent association was confirmed worldwide. This pattern was particularly evident in the Seven Countries Study.1 The observed variations in risk across different populations are largely due to the baseline risk values of these populations. For example, the Framingham Heart Study has shown that its results are applicable in any country by adjusting for baseline risk, suggesting a universal pattern in the relationship between cholesterol levels and cardiovascular risk. This has led to debate because the relationship has been oversimplified and presented as linear when it is not necessarily so. For example, an increase in total cholesterol of 0.5 mmol/L (about 20 mg/dL) correlates with a 12% change in mortality risk. In agreement with this observation, data from the Cholesterol Treatment Trialists' (CTT) Collaboration have shown that lowering low-density lipoprotein cholesterol (LDL-C) by 1 mmol/L reduces the risk of coronary heart disease by 22-23% reduction, which is consistent with data from clinical trials.
Article Metrics Graph
References
- Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-9. https://doi.org/10.1161/01.cir.97.15.1436
- Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274:131-6. https://www.ncbi.nlm.nih.gov/pubmed/7596000
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78. https://doi.org/10.1016/S0140-6736(05)67394-1
- Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829-39. https://doi.org/10.1016/S0140-6736(07)61778-4
- Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016; 27:473-83. https://doi.org/10.1097/MOL.0000000000000330
- Skeyni A, Pradignac A, Matz RL, et al. Cholesterol trafficking, lysosomal function, and atherosclerosis. Am J Physiol Cell Physiol 2024; 326:C473-C86. https://doi.org/10.1152/ajpcell.00415.2023
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38:2459-72. https://doi.org/10.1093/eurheartj/ehx144
- von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J 2023; 44:1394-407. https://doi.org/10.1093/eurheartj/ehac605
- Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 2019; 321:364-73. https://doi.org/10.1001/jama.2018.20045
- Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017; 390:1962-71. https://doi.org/10.1016/S0140-6736(17)32290-0
- Humphries SE, Ramaswami U, Hopper N. Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme? Curr Atheroscler Rep 2023; 25:1083-91. https://doi.org/10.1007/s11883-023-01177-0
- Tybjaerg-Hansen A, Nordestgaard BG, Christoffersen M. Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important? Eur Heart J 2023; 44:4196-8. https://doi.org/10.1093/eurheartj/ehad419
- Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem 2015; 61:533-43. https://doi.org/10.1373/clinchem.2014.234146
- Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022; 387:1923-34. https://doi.org/10.1056/NEJMoa2210645
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380:11-22. https://doi.org/10.1056/NEJMoa1812792
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020; 324:2268-80. https://doi.org/10.1001/jama.2020.22258